New therapeutic options opened by the molecular classification of gastric cancer

First-in-human Phase 1 CRISPR Gene Editing Cancer Trials: Are We Ready?

(2018) Francoise Baylis et al.   CURRENT GENE THERAPY

Phase II Study of Induction Chemotherapy with Docetaxel, Capecitabine, and Cisplatin Plus Bevacizumab for Initially Unresectable Gastric Cancer with Invasion of Adjacent Organs or Paraaortic Lymph Node Metastasis

(2018) Jwa Hoon Kim et al.   Cancer Research and Treatment

Importance of human peritoneal mesothelial cells in the progression, fibrosis, and control of gastric cancer: inhibition of growth and fibrosis by tranilast

(2017) Hiroto Saito et al.   Gastric Cancer

Regional differences in advanced gastric cancer: exploratory analyses of the AVAGAST placebo arm

(2017) Akira Sawaki et al.   Gastric Cancer

Knockdown of KRT17 by siRNA induces antitumoral effects on gastric cancer cells

(2017) Mihaela Chivu-Economescu et al.   Gastric Cancer

Efficacy and safety of ramucirumab (RAM) for metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma across age subgroups in two global phase 3 trials.

(2017) Kei Muro et al.   JOURNAL OF CLINICAL ONCOLOGY

A randomized, double-blind, multicenter phase III study evaluating paclitaxel with and without RAD001 in patients with gastric cancer who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC).

(2017) Salah-Eddin Al-Batran et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab (ONO-4538/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastro-esophageal junction cancer (AGC): A double-blinded, randomized, phase III trial.

(2017) Yoon-Koo Kang et al.   JOURNAL OF CLINICAL ONCOLOGY

HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

(2017) Manish A. Shah et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study

(2017) Peter C Thuss-Patience et al.   LANCET ONCOLOGY

Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial

(2017) Daniel V T Catenacci et al.   LANCET ONCOLOGY

Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

(2017) Scott J. Antonia et al.   NEW ENGLAND JOURNAL OF MEDICINE

Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability

(2017) Junhun Cho et al.   Oncotarget

Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: a multicenter AGEO study

(2017) Juliette Palle et al.   Oncotarget

First-line dose-dense chemotherapy with docetaxel, cisplatin, folinic acid and 5-fluorouracil (DCF) plus panitumumab in patients with locally advanced or metastatic cancer of the stomach or gastroesophageal junction: final results and biomarker analysis from an Italian oncology group for clinical research (GOIRC) phase II study

(2017) Gianluca Tomasello et al.   Oncotarget

Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) to select the optimal patients for matched therapy?

(2017) Young Kwang Chae et al.   Oncotarget

Identification and validation of a prognostic 9-genes expression signature for gastric cancer

(2017) Zhiqiang Wang et al.   Oncotarget

Targeted therapies for gastric cancer: failures and hopes from clinical trials

(2017) Maria Apicella et al.   Oncotarget

Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma

(2017) Manish A. Shah et al.   JAMA Oncology

Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer

(2017) Michael P. Chu et al.   JAMA Oncology

Molecular classifications of gastric cancers: Novel insights and possible future applications

(2017) Silvio Ken Garattini et al.   World Journal of Gastrointestinal Oncology

Gastric Cancer and Angiogenesis: Is VEGF a Useful Biomarker to Assess Progression and Remission?

(2017) Filipa Macedo et al.   Journal of Gastric Cancer

Efficacy and safety for Apatinib treatment in advanced gastric cancer: a real world study

(2017) Yong Zhang et al.   Scientific Reports

2OPhase 1 study of ramucirumab (R) plus durvalumab (D) in patients (pts) with locally advanced and unresectable or metastatic gastrointestinal or thoracic malignancies (NCT02572687); Phase 1a results

(2016) C-C. Lin et al.   ANNALS OF ONCOLOGY

Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma

(2016) S.-E. Al-Batran et al.   ANNALS OF ONCOLOGY

Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial

(2016) Jifang Gong et al.   BMC CANCER

Gene-expression profiling to predict responsiveness to immunotherapy

(2016) N B Jamieson et al.   CANCER GENE THERAPY

Dual Faces of IFN  in Cancer Progression: A Role of PD-L1 Induction in the Determination of Pro- and Antitumor Immunity

(2016) M. Mandai et al.   CLINICAL CANCER RESEARCH

Translating gastric cancer genomics into targeted therapies

(2016) Yvonne L.E. Ang et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

High microsatellite instability (MSI-H) colorectal carcinoma: a brief review of predictive biomarkers in the era of personalized medicine

(2016) Zoran Gatalica et al.   Familial Cancer

A randomized, double-blind, placebo-controlled phase III study of cisplatin plus a fluoropyrimidine with or without ramucirumab as first-line therapy in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (RAINFALL, NCT02314117).

(2016) Charles S. Fuchs et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction

(2016) Jin Li et al.   JOURNAL OF CLINICAL ONCOLOGY

Updated results for the advanced esophageal carcinoma cohort of the phase Ib KEYNOTE-028 study of pembrolizumab (MK-3475).

(2016) Toshihiko Doi et al.   JOURNAL OF CLINICAL ONCOLOGY

Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC—A Randomized Phase III Trial

(2016) J. Randolph Hecht et al.   JOURNAL OF CLINICAL ONCOLOGY

A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction

(2016) M. A. Shah et al.   ONCOLOGIST

Molecular alterations in gastric cancer with special reference to the early-onset subtype

(2016) Małgorzata Skierucha   WORLD JOURNAL OF GASTROENTEROLOGY

PI3K inhibitors as new cancer therapeutics: implications for clinical trial design

(2016) Cristian Massacesi et al.   OncoTargets and Therapy

siRNA targeting YAP gene inhibits gastric carcinoma growth and tumor metastasis in SCID mice

(2016) ZHOU ZHOU et al.   Oncology Letters

Therapeutic effect of apatinib on overall survival is mediated by prolonged progression-free survival in advanced gastric cancer patients

(2016) Lihong Huang et al.   Oncotarget

Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers

(2016) Sarah Derks et al.   Oncotarget

Pharmacokinetics and pharmacodynamics of rilotumumab: a decade of experience in preclinical and clinical cancer research

(2015) Y. Zhang et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005)

(2015) Ramesh K. Ramanathan et al.   CANCER

Phase II study of trastuzumab in combination with S-1 and cisplatin in the first-line treatment of human epidermal growth factor receptor HER2-positive advanced gastric cancer

(2015) Clarinda Chua et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Targeting vascular endothelial growth factor (VEGF) pathway in gastric cancer: Preclinical and clinical aspects

(2015) Omar Abdel-Rahman   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer

(2015) Min-Hee Ryu et al.   EUROPEAN JOURNAL OF CANCER

Is signet-ring cell carcinoma a specific entity among gastric cancers?

(2015) Thibault Voron et al.   Gastric Cancer

Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer

(2015) Kohei Shitara et al.   Gastric Cancer

S-1 and Cisplatin With or Without Nimotuzumab for Patients With Untreated Unresectable or Metastatic Gastric Cancer

(2015) Feng Du et al.   MEDICINE

AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules

(2015) S. M. Guichard et al.   MOLECULAR CANCER THERAPEUTICS

Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes

(2015) Razvan Cristescu et al.   NATURE MEDICINE

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

ARID1A gene mutation in ovarian and endometrial cancers (Review)

(2015) TAKASHI TAKEDA et al.   ONCOLOGY REPORTS

Signet-ring cell carcinoma of the stomach: Impact on prognosis and specific therapeutic challenge

(2015) Simon Pernot   WORLD JOURNAL OF GASTROENTEROLOGY

Targeting the PI3K/Akt signaling pathway in gastric carcinoma: A reality for personalized medicine?

(2015) Shikha Satendra Singh   WORLD JOURNAL OF GASTROENTEROLOGY

Apatinib for molecular targeted therapy in tumor

(2015) Haijun Zhang   Drug Design Development and Therapy

Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy

(2015) Ismael Riquelme et al.   Oncotarget

Recurrent Fusion Genes in Gastric Cancer: CLDN18-ARHGAP26 Induces Loss of Epithelial Integrity

(2015) Fei Yao et al.   Cell Reports

Signal Transduction in Cancer

(2015) R. Sever et al.   Cold Spring Harbor Perspectives in Medicine

Phase Ib/II study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) and tremelimumab as monotherapy or in combination, in patients with recurrent or metastatic gastric/gastroesophageal junction adenocarcinoma

(2015) Ronan J Kelly et al.   Journal for ImmunoTherapy of Cancer

Clinical significance of MET in gastric cancer

(2015) Mikito Inokuchi   World Journal of Gastrointestinal Oncology

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance

(2015) James Andrew McCubrey et al.   Oncotarget

A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer

(2014) Y-K Kang et al.   BRITISH JOURNAL OF CANCER

The emerging roles of ARID1A in tumor suppression

(2014) Ren-Chin Wu et al.   CANCER BIOLOGY & THERAPY

RhoA Mutations Identified in Diffuse Gastric Cancer

(2014) Jin Zhou et al.   CANCER CELL

Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer

(2014) Taroh Satoh et al.   Gastric Cancer

Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study)

(2014) Lin Shen et al.   Gastric Cancer

Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment ofHER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study

(2014) Taroh Satoh et al.   JOURNAL OF CLINICAL ONCOLOGY

The role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014

(2014) Paolo A Ascierto et al.   Journal of Translational Medicine

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

(2014) Hansjochen Wilke et al.   LANCET ONCOLOGY

Predictive biomarkers for the efficacy of cetuximab combined with cisplatin and capecitabine in advanced gastric or esophagogastric junction adenocarcinoma: a prospective multicenter phase 2 trial

(2014) Xiaotian Zhang et al.   MEDICAL ONCOLOGY

Comprehensive molecular characterization of gastric adenocarcinoma

(2014) Adam J. Bass et al.   NATURE

Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma

(2014) Miwako Kakiuchi et al.   NATURE GENETICS

Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer

(2014) Kai Wang et al.   NATURE GENETICS

HER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast Cancer

(2013) Nadia Harbeck et al.   Breast Care

Physiological roles of Rho and Rho effectors in mammals

(2013) Dean Thumkeo et al.   EUROPEAN JOURNAL OF CELL BIOLOGY

Ramucirumab: a novel antiangiogenic agent

(2013) Roopma Wadhwa et al.   Future Oncology

Identification of Molecular Subtypes of Gastric Cancer With Different Responses to PI3-Kinase Inhibitors and 5-Fluorouracil

(2013) Zhengdeng Lei et al.   GASTROENTEROLOGY

Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors

(2013) Meng Ling Choong et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Somatic Mutations and Deletions of the E-Cadherin Gene Predict Poor Survival of Patients With Gastric Cancer

(2013) Giovanni Corso et al.   JOURNAL OF CLINICAL ONCOLOGY

Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study

(2013) Atsushi Ohtsu et al.   JOURNAL OF CLINICAL ONCOLOGY

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

(2013) Charles S Fuchs et al.   LANCET

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial

(2013) Tom Waddell et al.   LANCET ONCOLOGY

Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial

(2013) Florian Lordick et al.   LANCET ONCOLOGY

ARID1A Alterations Are Associated with FGFR3-Wild Type, Poor-Prognosis, Urothelial Bladder Tumors

(2013) Cristina Balbás-Martínez et al.   PLoS One

Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent

(2013) M. Merchant et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Targeted genomic sequencing of pediatric Burkitt lymphoma identifies recurrent alterations in antiapoptotic and chromatin-remodeling genes

(2012) L. Giulino-Roth et al.   BLOOD

Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy

(2012) M. R. Green et al.   CLINICAL CANCER RESEARCH

Impact of Expression of Human Epidermal Growth Factor Receptors EGFR and ERBB2 on Survival in Stage II/III Gastric Cancer

(2012) M. Terashima et al.   CLINICAL CANCER RESEARCH

Targeting the EGFR signaling pathway in cancer therapy

(2012) Parthasarathy Seshacharyulu et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma

(2012) Cécile Guichard et al.   NATURE GENETICS

Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes

(2012) Zhi Jiang Zang et al.   NATURE GENETICS

Trastuzumab: Updated Mechanisms of Action and Resistance in Breast Cancer

(2012) Thuy Vu et al.   Frontiers in Oncology

Gene Expression Signature-Based Prognostic Risk Score in Gastric Cancer

(2011) J. Y. Cho et al.   CLINICAL CANCER RESEARCH

Intrinsic Subtypes of Gastric Cancer, Based on Gene Expression Pattern, Predict Survival and Respond Differently to Chemotherapy

(2011) Iain Beehuat Tan et al.   GASTROENTEROLOGY

Microsatellite instability in sporadic gastric cancer: its prognostic role and guidance for 5-FU based chemotherapy after R0 resection

(2011) Ji Yeong An et al.   INTERNATIONAL JOURNAL OF CANCER

Gene-Expression Signatures Can Distinguish Gastric Cancer Grades and Stages

(2011) Juan Cui et al.   PLoS One

Everolimus

(2010) P. J. Houghton   CLINICAL CANCER RESEARCH

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

(2010) Yung-Jue Bang et al.   LANCET

Prophylactic Total Gastrectomy (PTG) for Hereditary Diffuse Gastric Cancer (HDGC): The Newfoundland Experience with 23 Patients

(2009) P. C. Hebbard et al.   ANNALS OF SURGICAL ONCOLOGY

Rho GTPase function in tumorigenesis

(2009) R. Karlsson et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

Panitumumab

(2009) Eline A. Dubois et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number

(2008) M A Kim et al.   HISTOPATHOLOGY

Gastric cancer with high-level microsatellite instability: target gene mutations, clinicopathologic features, and long-term survival

(2008) Mario Falchetti et al.   HUMAN PATHOLOGY